Drug Profile
Preimplantation factor - BioIncept
Alternative Names: PIF-1; sPIF; synthetic preimplantation factorLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator BioIncept
- Developer BioIncept; University of Miami
- Class Anti-inflammatories; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune hepatitis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Autoimmune-hepatitis in USA (SC, Injection)
- 31 Dec 2018 BioIncept withdraws a phase II trial for Autoimmune disorders in USA prior to enrolment upon company's decision not to pursue this drug target at this time (SC) (NCT03593421)
- 31 Dec 2018 BioIncept withdraws a phase II trial prior to enrolment for Autoimmune hepatitis in USA as the company changed the focus of future drug development (SC) (NCT03593460)